Bilkie Robert M bought $5,574 worth of shares (600 units at $9.29) (SEC Form 4)

$GRF
Finance/Investors Services
Finance
Get the next $GRF alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bilkie Robert M

(Last) (First) (Middle)
225 E. MASON STREET, SUITE 802

(Street)
MILWAUKEE WI 53202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EAGLE CAPITAL GROWTH FUND, INC. [ GRF ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
04/19/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/19/2024 L 400 A $9.41 400 D
Common Stock 04/22/2024 L 200 A $9.4199 600 D
Common Stock 05/17/2024 P 600 A $9.29 1,200 D
Common Stock 1,764 I By Spouse's Trust(1)
Common Stock 1,229 I By Father's Trust(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reporting person disclaims ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or otherwise
Carrie Leahy, Attorney-in-Fact by Power of Attorney 05/24/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $GRF alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GRF

DatePrice TargetRatingAnalyst
More analyst ratings

$GRF
Press Releases

Fastest customizable press release news feed in the world

See more
  • Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash

    The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE:GRF) today declared a year-end distribution of $0.68 per share in cash. The record date for this distribution is November 29, 2024, and the payment date is December 19, 2024. On a preliminary basis, this distribution represents a combination of net investment income of $0.0754 per share, and long-term capital gains of $0.6046 per share. This preliminary information is subject to change. Shareholders will receive definitive information with respect to U. S. Federal income tax treatment. In addition, shareholders can access definitive tax information by going to the Fund's website after year-end. The Fund is a closed-end investment compan

    $GRF
    Finance/Investors Services
    Finance
  • Eagle Capital Growth Fund Declares Year-End Distribution of $0.35 Per Share in Cash

    The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE:GRF) today declared a year-end distribution of $0.35 per share in cash. The record date for this distribution is November 24, 2023, and the payment date is December 15, 2023. On a preliminary basis, this distribution represents a combination of net investment income of $0.07 per share, short-term capital gains of $0.03 per share, and long-term capital gains of $0.25 per share. This preliminary information is subject to change. Shareholders will receive definitive information with respect to U. S. Federal income tax treatment. In addition, shareholders can access definitive tax information by going to the Fund's website after year-end. T

    $GRF
    Finance/Investors Services
    Finance
  • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

    BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

    $GRF
    $GRFS
    Finance/Investors Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GRF
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GRF
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GRF
SEC Filings

See more

$GRF
Leadership Updates

Live Leadership Updates

See more
  • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

    BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

    $GRF
    $GRFS
    Finance/Investors Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GRF
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more